Posted on April 3rd, 2012

David Cocker’s Presentation at the 10th Annual SFE & Commercial Excellence Europe 2012

“This year’s SFE brought together some of Europe’s leading commercial innovators in the pharmaceutical space, including excellent keynotes and hard hitting presentations that removed the gloss and placed emphasis on the touch challenges facing Pharma today.

A couple of clear messages emerged:

• Dr. Marc Czarka’s talk on market access and the rapidly changing landscape where governments and patients are going to vet the value of new medicines reaching national markets places new emphasis on patient advocacy and their product perception.

• Emergence of the digi-rep from Roche’s Andreas Claus Kistner, the age of the iPad is upon us and printed material is giving way to apps and animation. But there is more. AstraZeneca’s Florent Edouard closing the complete electronic loop from web to rep, the concept of a seemleass corporate digital eco-system allowing reps to bring the most relevant information to their markets while at the same time gathering compliant feedback to the corporate classification. The traditional CRM concept is inadequate, too expensive and fails to deliver the needs of an evolving market.

• Actelion’s Christoph Schmidt highlighted the challenges in orphan drug specialty selling and precisely described the change in paradigm from primary to specialty care.

Congratulations to the eyeforpharma team, a dynamic and focused group of individuals working hard to bring a diverse and exciting program. For me the bar has been raised and I look forward to next year’s event. “
David J. Cocker

If you want to download a copy of David Cocker’s presentation, please click here.

Tags: Business, General, Meetings/Events

Posted on February 23rd, 2012

David Cocker to present at SFE Europe, March 2012

27th – 29th March 2012 | Hotel Rey Juan Carlos I, Barcelona

“Public Disclosure: An Inconvenient Truth”

10th Anniversary SFE & Commercial Excellence Europe

On March 28th David Cocker will be speaking at the SFE Europe & Commercial Excellence 2012 conference in Barcelona in Track 3: Sell More: Engage all your new stakeholders.

Track 3 will concentrate on six sessions including,

• Evolving customers
• Influence HCPs, payers, advocates and patients
• Patient value
• Identification and tracking of KOLs
• Stakeholder Relationship Management

This conference will focus on the evolving needs of the customer through industry’s leading ideas. With over 1000 attendees, 9 tracks and 10 workshops, David will be presenting alongside 70 other handpicked speakers.

To download a copy of the program, please click here.

Tags: Business, General, Meetings/Events

Posted on February 22nd, 2012

New normScan Version 3.1

We are happy to announce that we have added more information on the regulatory status of standards and that the graphical time evolution per standard now reflects the nationally adopted versions of international standards to normScan V.3.1.

normScan can now also indicate standards referenced by the FDA, and monitor these on a monthly basis alerting you by email to any changes.

For further insights, normScan also now offers three sub-tabs per standard; properties, attachments and the evolution.

If you would like to learn more about normScan and how it can help you monitor standards, please click here or contact us directly at .(JavaScript must be enabled to view this email address).

Tags: Business, General, Product news

Posted on February 21st, 2012

MDCPartners would like to introduce two new members of their expanding team

MDCPartners is constantly working on ideas to improve both ta-Scan and normScan as both business and regulatory intelligence tools. As such, we are pleased to announce two new members of our team to help us with our continued improvement efforts:

Joke Lievens, PhD
Business Consultant

Joke initially trained as a research scientist at the KULeuven Center for Molecular and Vascular Biology, where she completed a thesis on the development of HDL-cholesterol raising gene therapies for cardiovascular diseases. After obtaining her PhD, she held positions in the biopharmaceutical industry and academia in Belgium and France.

For INSERM/GIS Institut des maladies rares she has managed a large EU project on rare diseases and worked on the integration of next generation DNA sequencing in rare diseases research.

In the biopharmaceutical industry she has been involved in the development of targeted therapies for cancer. She held responsibility and developed operational expertise in the management of intellectual property portfolios and the search and evaluation of licensing opportunities for oncology drugs.

Besides her PhD in medical sciences, Joke holds a masters degree in bioengineering and is preparing a post-graduate degree in pharmaceutical medicine.

She is fluent in English, French and Dutch.

Jorge Saint-Aubyn, MSc
IT Project Manager

Jorge’s scientific background can be explained with his degree in Applied Mathematics from Simon Bolivar University (USB Venezuela) with courses in statistics from Lund University (Sweden).
In addition he obtained a MSc Degree in Operations Research from Maastricht University (The Netherlands) with courses in Machine Learning and Text Mining.

Along his career, he successfully completed assorted research in the fields of data analysis, IT industry and bioinformatics. For Zi-Decuma, Lund he trained as a researcher on a project implementing statistical methods to improve the clarity of handwriting on electronic tablets. He worked for CESMA (Statistics and Mathematical Software Center) at USB reviewing the implementions of Bayesian Kriging interpolation applied to produce digital maps of monthly rainfall for Venezuela and prepared the data input.

During his Master Thesis research, he investigated cardiac proteins and miRNA interactions that affect cardiac diseases using bioinformatics tools in collaboration with the Cardiology Department at Maastricht University. His interests rely mainly in the power of data visualization and information discovering.

He speaks Spanish, English and French.

Tags: Business, General